Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03360123 · ClinicalTrials.gov registry record · NA
Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient
A NA study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT03360123: Completed NA study, sponsored by University of Pittsburgh.
NCT03360123 is a NA study that has completed, run by University of Pittsburgh. The registered enrollment target is 4 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03360123, a NA study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study will evaluate the perceptions of the effects of two anxiolytic medications commonly used during dental treatment in patients weighing 40 kilograms or more.
Primary Outcome
Parents will complete a 4 questions post-treatment survey after the 2nd dental appointment.
Interventions
- DRUG Midazolam Hydrochloride 2Mg/mL Syrup
- DRUG Triazolam 0.125 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2018-04-11 |
| Phase | NA |
What the finished NCT03360123 record still lists
NCT03360123 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Midazolam Hydrochloride 2Mg/mL Syrup is the first listed.
NCT03360123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03360123 about?
NCT03360123 is a clinical study titled "Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient". This study will evaluate the perceptions of the effects of two anxiolytic medications commonly used during dental treatment in patients weighing 40 kilograms or more.
What is the current status of trial NCT03360123?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2018-01-26. Estimated completion is 2018-04-11.
What interventions are being tested in trial NCT03360123?
The interventions under investigation include: Midazolam Hydrochloride 2Mg/mL Syrup (DRUG), Triazolam 0.125 MG (DRUG).
Who is sponsoring clinical trial NCT03360123?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03360123's enrollment target sits among peer trials
4 1996th of 2000 higher than 5 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI